OrbiMed’s CR Bard Inc. BCR Stock Holding History

OrbiMed’s Portfolio BCR Stock Details BCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-58,000	Closed	-$14.4M	–	152
2017 Q1	$14.4M	Hold	58,000	–	–	0.16%	85
2016 Q4	$13M	Hold	58,000	–	–	0.17%	77
2016 Q3	$13M	Buy	58,000 +35,000	+152%	+$7.88M	0.15%	91
2016 Q2	$5.41M	Buy	+23,000	New	+$5M	0.06%	111
2013 Q4	–	Sell	-38,000	Closed	-$4.38M	–	153
2013 Q3	$4.38M	Hold	38,000	–	–	0.08%	104
2013 Q2	$4.13M	Buy	+38,000	New	+$3.95M	0.09%	106

Other funds holding BCR

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ACPU

Arrowgrass Capital Partners (US) Dover, Delaware $380M AUM 20.87% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

OrbiMed's BCR Position: Q2 2017 in Review

OrbiMed sold out of CR Bard Inc. (BCR) in Q2 2017, closing a stake of 58,000 shares — an estimated $14.4M sold.

OrbiMed first reported a position in BCR in Q2 2013 and held it in 6 quarters. The position peaked at $14.4M in Q1 2017. 675 funds tracked by Wall St. Rank hold BCR as of Q2 2017.

OrbiMed reported no remaining CR Bard Inc. position as of Q2 2017 after selling out during the quarter.
OrbiMed sold 58,000 CR Bard Inc. shares in Q2 2017, an estimated $14.4M.
OrbiMed first reported a position in CR Bard Inc. in Q2 2013 and held it in 6 quarters.
OrbiMed's CR Bard Inc. position peaked at $14.4M in Q1 2017.
675 funds tracked by Wall St. Rank held CR Bard Inc. as of Q2 2017.

Based on OrbiMed's 13F filing for Q2 2017, filed 14 Aug 2017.